Development and clinical translation of ex vivo gene therapy

Xiaomo Wu,Xiaorong He,Fahui Liu,Xiaochang Jiang,Ping Wang,Jinyan Zhang,Ju Jiang

DOI: https://doi.org/10.1016/j.csbj.2022.06.015

IF: 6.155

2022-01-01

Computational and Structural Biotechnology Journal

Abstract:Retroviral gene therapy has emerged as a promising therapeutic modality for multiple inherited and acquired human diseases. The capability of delivering curative treatment or mediating therapeutic benefits for a long-term period following a single application fundamentally distinguishes this medical intervention from traditional medicine and various lentiviral/γ-retroviral vector-mediated gene therapy products have been approved for clinical use. Continued advances in retroviral vector engineering, genomic editing, synthetic biology and immunology will broaden the medical applications of gene therapy and improve the efficacy and safety of the treatments based on genetic correction and alteration. This review will summarize the advent and clinical translation of <i>ex vivo</i> gene therapy, with the focus on the milestones during the exploitation of genetically engineered hematopoietic stem cells (HSCs) tackling a variety of pathological conditions which led to marketing approval. Finally, current statue and future prospects of gene editing as an alternative therapeutic approach are also discussed.

biochemistry & molecular biology